Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocol.
Penfold S, Adegnika AA, Asogun D, Ayodeji O, Azuogu BN, Fischer WA 2nd, Garry RF, Grant DS, Happi C, N'Faly M, Olayinka A, Samuels R, Sibley J, Wohl DA, Accrombessi M, Adetifa I, Annibaldis G, Camacho A, Dan-Nwafor C, Deha ARE, DeMarco J, Duraffour S, Goba A, Grais R, Günther S, Honvou ÉJJP, Ihekweazu C, Jacobsen C, Kanneh L, Momoh M, Ndiaye A, Nsaibirni R, Okogbenin S, Ochu C, Ogbaini E, Logbo ÉPMA, Sandi JD, Schieffelin JS, Verstraeten T, Vielle NJ, Yadouleton A, Yovo EK; Enable Protocol authorship group. Penfold S, et al. Among authors: verstraeten t. PLoS One. 2023 Mar 30;18(3):e0283643. doi: 10.1371/journal.pone.0283643. eCollection 2023. PLoS One. 2023. PMID: 36996258 Free PMC article.
A prospective cohort study of SARS-CoV-2 infection-induced seroconversion and disease incidence in German healthcare workers before and during the rollout of COVID-19 vaccines.
Gehring S, Kowalzik F, Okasha O, Engelmann T, Schreiner D, Jensen C, Mähringer-Kunz A, Hartig-Merkel W, Mai Phuong Tran T, Oostvogels C, Verstraeten T. Gehring S, et al. Among authors: verstraeten t. PLoS One. 2024 Jan 30;19(1):e0294025. doi: 10.1371/journal.pone.0294025. eCollection 2024. PLoS One. 2024. PMID: 38289913 Free PMC article.
Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP.
Costa Clemens SA, Fortaleza CMCB, Crowe M, Tasca KI, Spadaro AG, Souza-Neto JA, Grotto RMT, Sider R, Jimeno J, Verstraeten T, Clemens R. Costa Clemens SA, et al. Among authors: verstraeten t. Front Public Health. 2022 Oct 13;10:1016402. doi: 10.3389/fpubh.2022.1016402. eCollection 2022. Front Public Health. 2022. PMID: 36311567 Free PMC article.
Economic Evaluation of Universal Varicella Vaccination in Mexico.
Chacon-Cruz E, Meroc E, Costa-Clemens SA, Clemens R, Verstraeten T. Chacon-Cruz E, et al. Among authors: verstraeten t. Pediatr Infect Dis J. 2022 May 1;41(5):439-444. doi: 10.1097/INF.0000000000003448. Pediatr Infect Dis J. 2022. PMID: 34966138 Free PMC article.
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, Garcia Lopez CA, Gonzales L, Granados González MA, Gorini N, Grobusch MP, Hrabar AD, Junker H, Kimura A, Lanata CF, Lehmann C, Leroux-Roels I, Mann P, Martinez-Reséndez MF, Ochoa TJ, Poy CA, Reyes Fentanes MJ, Rivera Mejia LM, Ruiz Herrera VV, Sáez-Llorens X, Schönborn-Kellenberger O, Schunk M, Sierra Garcia A, Vergara I, Verstraeten T, Vico M, Oostvogels L; HERALD Study Group. Kremsner PG, et al. Among authors: verstraeten t. Lancet Infect Dis. 2022 Mar;22(3):329-340. doi: 10.1016/S1473-3099(21)00677-0. Epub 2021 Nov 23. Lancet Infect Dis. 2022. PMID: 34826381 Free PMC article. Clinical Trial.
120 results